Trial Information
The Molecular Characterization of Multiple Myeloma at Relapse
Inclusion Criteria:
- patients newly diagnosed with multiple myeloma and at the same time eligible for high
dose chemotherapy and autologous stem cell transplantation
- patients with multiple myeloma experiencing relapse after high dose chemotherapy and
autologous stem cell transplantation
Exclusion Criteria:
- for newly diagnosed patients: age or comorbidity preventing high dose chemotherapy
and autologous stem cell transplantation,
- for all patients: age below 18, physical or psychological incapability to give an
informed consent.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Molecular characteristics (by FISH, SNP, GEP, miRNA)
Outcome Time Frame:
0-3 years
Safety Issue:
No
Principal Investigator
N Emil U Hermansen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Rigshospitalet, Denmark
Authority:
Denmark: Danish Dataprotection Agency
Study ID:
959593931/Emil Hermansen
NCT ID:
NCT00639054
Start Date:
March 2008
Completion Date:
January 2016
Related Keywords:
- Multiple Myeloma
- classification
- diagnosis
- genetics
- mortality
- pathology
- Multiple Myeloma
- Neoplasms, Plasma Cell